Literature DB >> 29956084

Everolimus shortens survival of newly diagnosed glioblastoma patients.

Eric T Wong1, Kenneth D Swanson2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29956084     DOI: 10.1007/s11060-018-2937-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

1.  A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Authors:  Prakash Chinnaiyan; Minhee Won; Patrick Y Wen; Amyn M Rojiani; Maria Werner-Wasik; Helen A Shih; Lynn S Ashby; Hsiang-Hsuan Michael Yu; Volker W Stieber; Shawn C Malone; John B Fiveash; Nimish A Mohile; Manmeet S Ahluwalia; Merideth M Wendland; Philip J Stella; Andrew Y Kee; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

2.  Corticosteroids compromise survival in glioblastoma.

Authors:  Kenneth L Pitter; Ilaria Tamagno; Kristina Alikhanyan; Amira Hosni-Ahmed; Siobhan S Pattwell; Shannon Donnola; Charles Dai; Tatsuya Ozawa; Maria Chang; Timothy A Chan; Kathryn Beal; Andrew J Bishop; Christopher A Barker; Terreia S Jones; Bettina Hentschel; Thierry Gorlia; Uwe Schlegel; Roger Stupp; Michael Weller; Eric C Holland; Dolores Hambardzumyan
Journal:  Brain       Date:  2016-03-28       Impact factor: 13.501

3.  Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.

Authors:  E T Wong; E Lok; S Gautam; K D Swanson
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.